Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 3352   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Year : 2017  |  Volume : 8  |  Issue : 1  |  Page : 25-28

Cost-effectiveness of glaucoma management with monotherapy medications in Egypt

1 Lecturer, Military Medical Academy, Cairo, Egypt
2 Associate Professor, Military Medical Academy, Cairo, Egypt
3 Department of Medical services, Consultant eye- surgeon FRCS Ed. Ophthalmology, Cairo, Egypt
4 Faculty of Pharmacy, Cairo University, Cairo, Egypt

Correspondence Address:
Amal Abd-Elaal El-Khamery
Military Medical Academy, Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2231-4040.197384

Rights and Permissions

Glaucoma is a serious chronic ophthalmic disease since it causes irreversible visual disability if untreated can lead to blindness. Treatment options include medications (classified into five major classes of drugs which are muscarinic cholinergic agonists, alpha-2 adrenergic agonists, beta-1 adrenergic antagonists, prostaglandins [PGs], and carbonic anhydrase inhibitors); use of laser therapy or conventional surgery. Pharmacoeconomic analysis helps in choosing among this variety of treatments. There is a great need for such analysis in Egypt since undergoing of it in different countries or societies may produce different results. This work aimed to compare cost-effectiveness of bimatoprost 0.03% once daily versus brimonidine 0.2% twice daily and timolol 0.5% twice daily as monotherapy treatment in Egyptian patients with open-angle glaucoma or ocular hypertension. Clinical data revealed that all treatments decreased intraocular pressure (IOP) significantly but bimatoprost 0.03% showed the highest efficacy (27.7% decrease in IOP from baseline), while timolol 0.5% reduced IOP by 22.5% then brimonidine 0.2% which decreased IOP by 20.8%. From the cost-effectiveness view, it would be preferable to initiate treatment with timolol in case of absence of any contraindications. PG analog can be used as add-on therapy in low responder patients or as alternative treatment in case of presence of contraindication to use of beta blockers.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded419    
    Comments [Add]    
    Cited by others 3    

Recommend this journal